In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

EHJ – Cardiovascular Pharmacotherapy

Specific Focus on Clinical Cardiovascular Pharmacology

 

The European Heart Journal – Cardiovascular Pharmacotherapy (EHJ-CVP) is the official journal of the European Society of Cardiology and the ESC Working Group on Cardiovascular Pharmacotherapy. The journal reports on the interpretation and integration of new scientific developments  to improve the pharmacological treatment of patients with cardiovascular disease.

It publishes original articles on clinical research, with new and established drugs and methods, as well as meta-analysis and topical reviews.

 

Fast Facts

  • Editor-in-chief: Stefan Agewall FESC, NO
  • Current volume: 8 (year 2022)
  • Issues per subscription: 8
  • Impact Factor 2020: 6.617

Advertising, Reprints and Supplements

Oxford University Press (publisher of the ESC journals) offers a number of services which help you reach ESC audiences or re-use the content published by the journals for educational purposes:

• Print and digital advertising puts your marketing message in front of ESC journal readers
• A peer-reviewed supplement communicates scientific research via a themed collection of papers
• Reprints and ePrints are an ideal format for dissemination of published papers
• Licensing ESC content for excerpted local editions or CME ensures the best-possible content for your region

Please contact OUP at jnlsadvertising@oup.com for further information.

Editor in Chief History

Name Start Date End Date
 Professor Stefan Agewall 01/01/2015  
Updates on latest articles

Updates on latest articles

 

Receive the table of contents in your mailbox.

Track topics and authors important to you and receive articles in your mailbox.

For Authors

Before being published, all manuscripts go through double-blind, peer review by experienced international experts.


This Content Component encountered an error